Innealta Capital LLC Has $294,000 Stock Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

Innealta Capital LLC boosted its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 78.1% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 19,981 shares of the company’s stock after purchasing an additional 8,760 shares during the period. Innealta Capital LLC’s holdings in Elanco Animal Health were worth $294,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of ELAN. Benjamin F. Edwards & Company Inc. lifted its position in shares of Elanco Animal Health by 337.7% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company’s stock valued at $26,000 after buying an additional 1,361 shares during the last quarter. ORG Wealth Partners LLC bought a new stake in Elanco Animal Health in the 3rd quarter valued at $29,000. ORG Partners LLC acquired a new stake in Elanco Animal Health during the 2nd quarter valued at $31,000. nVerses Capital LLC acquired a new stake in Elanco Animal Health during the 2nd quarter valued at $32,000. Finally, Quarry LP bought a new position in Elanco Animal Health during the second quarter worth $40,000. Institutional investors own 97.48% of the company’s stock.

Insider Buying and Selling at Elanco Animal Health

In other Elanco Animal Health news, Director Michael J. Harrington purchased 3,500 shares of the firm’s stock in a transaction on Thursday, August 22nd. The stock was purchased at an average cost of $14.85 per share, for a total transaction of $51,975.00. Following the acquisition, the director now owns 81,094 shares in the company, valued at approximately $1,204,245.90. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Jeffrey N. Simmons acquired 100,000 shares of the firm’s stock in a transaction on Monday, August 12th. The stock was purchased at an average cost of $13.01 per share, with a total value of $1,301,000.00. Following the acquisition, the chief executive officer now owns 145,000 shares of the company’s stock, valued at approximately $1,886,450. This trade represents a 200.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Michael J. Harrington purchased 3,500 shares of the firm’s stock in a transaction that occurred on Thursday, August 22nd. The shares were bought at an average price of $14.85 per share, with a total value of $51,975.00. Following the acquisition, the director now directly owns 81,094 shares of the company’s stock, valued at $1,204,245.90. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 0.57% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on ELAN. Barclays cut their target price on shares of Elanco Animal Health from $22.00 to $19.00 and set an “overweight” rating for the company in a research note on Monday, October 28th. Stifel Nicolaus restated a “buy” rating and set a $20.00 price objective on shares of Elanco Animal Health in a report on Thursday, September 19th. Finally, Morgan Stanley lowered Elanco Animal Health from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $17.00 to $15.00 in a research note on Thursday, September 19th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $17.00.

Elanco Animal Health Stock Down 0.3 %

NYSE ELAN opened at $12.60 on Monday. The company has a market cap of $6.23 billion, a price-to-earnings ratio of -4.94, a PEG ratio of 1.32 and a beta of 1.41. Elanco Animal Health Incorporated has a 1-year low of $8.75 and a 1-year high of $18.80. The company has a current ratio of 2.93, a quick ratio of 1.75 and a debt-to-equity ratio of 0.92. The company has a 50 day moving average of $14.11 and a 200-day moving average of $14.73.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Thursday, August 8th. The company reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.24 by $0.06. The firm had revenue of $1.18 billion for the quarter, compared to the consensus estimate of $1.15 billion. Elanco Animal Health had a negative net margin of 27.94% and a positive return on equity of 7.29%. The business’s revenue for the quarter was up 12.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.18 earnings per share. On average, equities research analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.